secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001493152-26-021861
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Q1 2026: CyPath Lung sales +146% YoY, revenue $1.4M, net loss $3.6M
-------------------------------------------------------------------------------

- CyPath Lung unit sales rose 146% YoY; testing revenue up 114% to $361,000.
- Total revenue $1.4M, down 27% from $1.9M due to discontinuing unprofitable pathology services.
- Net loss $3.6M ($0.81/share) vs $2.7M ($4.80/share) in Q1 2025; cash $3.1M.
- Physician offices ordering CyPath Lung increased 69% YoY; company expects acceleration.
- Launched DoD-funded longitudinal trial; Brooke Army Medical Center study for asthma/COPD companion tests.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226021861/0001493152-26-021861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226021861/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-021861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer